Colorectal Cancer – Treatments | Gastrointestinal Cancer
RAS mutations: impact on treatment outcome | Colorectal Cancer
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Study reveals potential target for precision colorectal cancer treatment - Redox Medicine Society
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon Cancer
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 3 (2021)
Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis | Bentham Science
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy | Annals of Surgical Oncology
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
Colorectal Cancer
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients | Nature Communications
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
The Trouble With KRAS - Cancer Commons
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
